There's no standardized microdosing protocol yet that's part of why this conversation is still emerging
Research published in Oxidative Medicine and Cellular Longevity established that glycine is the rate-limiting factor in glutathione production for many people
In an 899-page budget bill approved the final day of the spring legislative session last May, a four-sentence provision codified for the first time that carriers in the state program shall provide coverage for all types of injectable medicines prescribed on-label or off-label to improve glucose or weight loss for use by adults diagnosed or previously diagnosed with prediabetes, gestational diabetes, or obesity. But who gave the go-ahead to include those four sentences in the bill, adding what could be hundreds of millions of dollars of coverage costs, is difficult to say
[1] Other safety considerations include risk of gallbladder disease, pancreatitis, diabetic retinopathy complications (particularly with rapid A1c reduction), and hypersensitivity reactions
Evaluation of the effects of topical tripeptide-copper complex and zinc oxide on open-wound healing in rabbits